Monday - April 6, 2026
UAB compound designated orphan drug to advance towards a new treatment for spinal cord injury
March 23, 2026
BARCELONA, Spain, March 23 -- The Autonomous University of Barcelona issued the following news:

* * *

UAB compound designated orphan drug to advance towards a new treatment for spinal cord injury

*

The European Medicines Agency (EMA) has designated as an orphan drug a compound based on the bioactive lipid molecule Maresin-1 (MaR1), currently being investigated by a research team from the UAB for the treatment of spinal cord injuries.

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products